Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) Short Interest Update

Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) was the target of a significant growth in short interest in April. As of April 15th, there was short interest totaling 1,276 shares, a growth of 937.4% from the March 31st total of 123 shares. Based on an average daily volume of 5,584 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.0% of the shares of the stock are sold short.

Hedge Funds Weigh In On Invesco Biotechnology & Genome ETF

Several large investors have recently made changes to their positions in PBE. Royal Bank of Canada grew its position in shares of Invesco Biotechnology & Genome ETF by 22.3% during the first quarter. Royal Bank of Canada now owns 75,402 shares of the company’s stock worth $4,783,000 after purchasing an additional 13,767 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in Invesco Biotechnology & Genome ETF by 5.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 37,657 shares of the company’s stock worth $2,389,000 after purchasing an additional 2,103 shares during the period. Osaic Holdings Inc. boosted its stake in Invesco Biotechnology & Genome ETF by 9.9% in the 2nd quarter. Osaic Holdings Inc. now owns 9,441 shares of the company’s stock worth $605,000 after purchasing an additional 852 shares during the period. Sowell Financial Services LLC purchased a new stake in Invesco Biotechnology & Genome ETF during the 3rd quarter valued at approximately $208,000. Finally, Joel Isaacson & Co. LLC bought a new stake in shares of Invesco Biotechnology & Genome ETF during the third quarter valued at approximately $211,000.

Invesco Biotechnology & Genome ETF Stock Performance

Shares of NYSEARCA PBE traded down $0.21 during midday trading on Friday, reaching $79.82. The stock had a trading volume of 4,381 shares, compared to its average volume of 7,178. The company has a market capitalization of $249.84 million, a price-to-earnings ratio of 20.44 and a beta of 0.76. Invesco Biotechnology & Genome ETF has a 12-month low of $59.01 and a 12-month high of $85.73. The stock has a 50-day moving average of $79.52 and a 200-day moving average of $79.45.

Invesco Biotechnology & Genome ETF Company Profile

PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies. The Fund will normally invest at least 90% of its total assets in common stocks that consists of the Index. The Index is designed to provide capital appreciation by evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.